Jupiter Neurosciences continues to advance its proprietary JOTROL™ resveratrol-based platform through clinical development focused on Parkinson’s disease and consumer-facing longevity supplements under the Nugevia™ brand. The latest quarterly report confirms maintenance of previously disclosed risk factors, with no material updates but persistent challenges related to liquidity, Nasdaq listing compliance, and dependence on Aquanova’s licensed NovaSOL® technology. Growth hinges on successful trial outcomes, market adoption of Nugevia products, and capital-raising execution within tight financial constraints.